Bachem Holding AG (BCHMY)

OTCMKTS · Delayed Price · Currency is USD
9.80
-0.35 (-3.45%)
May 13, 2026, 9:37 AM EST
Market Cap7.40B +65.9%
Revenue (ttm)876.56M +14.8%
Net Income187.64M +23.7%
EPS2.50 +23.8%
Shares Outn/a
PE Ratio39.41
Forward PE31.07
Dividend0.07 (0.66%)
Ex-Dividend DateMay 5, 2026
Volumen/a
Average Volume13,324
Open9.80
Previous Close10.15
Day's Range9.80 - 9.80
52-Week Range5.97 - 12.54
Beta0.78
RSI62.25
Earnings DateJul 30, 2026

About Bachem Holding AG

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, an... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1971
Employees 2,595
Stock Exchange OTCMKTS
Ticker Symbol BCHMY

Financial Performance

In 2025, Bachem Holding AG's revenue was 695.07 million, an increase of 14.84% compared to the previous year's 605.26 million. Earnings were 148.79 million, an increase of 23.74%.

Financial numbers in CHF Financial Statements

News

Bachem Holding AG Earnings Call Transcript: H2 2025

Sales grew 14.8% to CHF 695.1 million in 2025, with EBITDA margin at 30.9%. 2026 guidance targets 35%-45% sales growth and low 30s% EBITDA margin, driven by Building K ramp-up and strong demand for complex peptides and oligonucleotides.

2 months ago - Transcripts

Bachem Holding AG Earnings Call Transcript: H1 2025

Sales grew 30.2% to CHF 313M with EBITDA up 64% and margin at 29.1%. CapEx and workforce expanded to support future growth, and guidance was raised for 2024 with strong demand in peptides and oligonucleotides.

10 months ago - Transcripts